Analysis of tissue biomarkers expressed in ovarian cancer samples



Prana Biotechnology has announced that a recent independent study conducted by Massachusetts General Hospital (MGH) has demonstrated that the Company’s Metal-Protein Attenuating Compounds (MPACs) could halt Alzheimer’s pathology. The study published in the November edition of Annals of Neurology shows that the administration of the anesthetic gas isoflurane can spur the production of amyloid-beta protein,

Full Post: Prana Biotechnology’s compound could halt Alzheimer’s pathology

In a new analysis of tissue biomarkers expressed in ovarian cancer samples, published by PLoS Medicine, David Huntsman and his colleagues from Vancouver General Hospital suggest that substantial differences exist between ovarian cancer subtypes which should be reflected in patient management.

Although ovarian cancer is not the most common gynecologic cancer in women, the disease contributes a substantial burden of mortality in part because symptoms are nonspecific and the disease presents late in its course.

As part of their research, Huntsman and coworkers measured expression levels of 21 proteins in 500 ovarian cancer samples which had been collected by an ovarian cancer registry serving British Columbia, Canada; they then correlated expression of these biomarkers with patient survival data following standardized treatment. Their analyses studied associations between biomarker expression and survival for all cancers grouped together, as well as studying the five major ovarian cancer subtypes separately (high-grade serous, low-grade serous, clear cell, endometrioid, and mucinous carcinomas).

Although biomarker expression was stable across disease stages within a given subtype, the associations between specific biomarkers and disease outcome differed substantially between subtypes. As a result, the researchers propose that “our study offers persuasive evidence supporting the view that ovarian carcinoma subtypes are different diseases.”

http://www.plos.org/

Link




A protein known to inhibit the growth of ovarian cancer works in part by forcing cancer cells to eat themselves until they die, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 15 issue of Cancer Research. The research team also found that expression of the protein, known as

Full Post: PEA-15 protein points to potential targeted approach for ovarian cancer



Levels of two proteins in a woman’s ovarian cancer are strongly associated with her likelihood of survival, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Dec. 18 issue of the New England Journal of Medicine. The study shows that women with high levels of

Full Post: Levels of two proteins impact survival in ovarian cancer



Researchers from Boston University School of Medicine (BUSM) have demonstrated that a recently discovered class of molecule called microRNA (miRNAs), regulate the gene expression changes in airway cells that occur with smoking and lung cancer. These findings, which appear in the on-line early edition of journal Proceedings of the National Academy of Sciences, may lead

Full Post: Discovery of potential biomarker for smoking-related lung diseases



Obesity affects health in several ways, but new research shows obesity can have minimal impact on ovarian cancer survival. A study by researchers at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center found ovarian cancer survival rates are the same for obese and non-obese women if their chemotherapy doses are closely matched to

Full Post: Obesity has minimal impact on ovarian cancer survival



bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, reported today findings from three studies using the company’s molecular breast cancer assay to predict risk of disease recurrence in individual patients. Data from the studies were presented this week at the San Antonio Breast Cancer Symposium (SABCS). The Theros

Full Post: Three studies of bioTheranostics molecular breast cancer diagnostics presented at symposium